Osteomalacia after gastrectomy

Sir,—I congratulate Bisballe et al (Gut 1991; 32: 1303–7) essay on postgastrectomy patients for metabolic bone disease. All too often, we, as physicians caring for patients with gastrointestinal problems that lead to abnormal bone nutrition and metabolism—that is, postgastrectomy metabolic bone disease, small bowel malabsorption, and states of diminished oral intake, ignore the patients’ developing bone disease because the process is insidious and the patients are often asymptomatic until the disease is so profound that much of it may be irreversible.

I must take issue, however, with the authors’ conclusion advocating supplemental vitamin D for all postgastrectomy patients. The authors have found evidence of bone abnormalities by histomorphometry in up to 62% of 51 patients, but only eight patients were considered to have osteomalacia. It is not clear that vitamin D supplementation is beneficial in non-osteomalacia bone disorders.

The authors suggest that the low mean levels of 25-hydroxyvitamin D are relevant and thus warrant supplementation. Yet, five of eight patients with abnormal osteomalacia had normal levels, highlighting the lack of value serum measurements may have in predicting bone disorder diagnoses. The authors do not state how many of their osteomalacia patients had levels that were abnormal (they state only that the mean overall was abnormal). That 1,25-dihydroxyvitamin D levels, the active circulating vitamin D metabolite, were normal in these patients, underscores how complex vitamin D metabolism is and how serum values may not be predictive of an abnormality.

Although the authors agree in their final paragraph that serum biochemical results are of limited value, they use these results as the premise for a therapeutic intervention. They showed that patients who took vitamin D supplementation had higher levels of serum 25-hydroxyvitamin D. It is not sufficient to recommend vitamin D therapy simply because patients have metabolic bone disease. Vitamin D supplements in excess doses can be toxic and may not normalize serum levels. There is no indication that those patients on supplements had less bony abnormalities on histomorphometry. In fact, half of the patients with osteomalacia were using supplementation.

To determine whether vitamin D is of therapeutic benefit, a study is needed whereby vitamin D therapy is compared with placebo in a randomised blinded group of postgastrectomy patients and not where the use of vitamin D in a group of patients is compared with a non-diseased control group. Oral ingestion of dietary vitamin D needs to be controlled. Investigators of such a study would need to show that bone histomorphometry improved or did not worsen over time while on therapy.

Vogelsang et al1 showed that overall, a group of Crohn’s disease patients randomised to vitamin D 1000 IU/day therapy did not have a statistically significant improvement in bone mineral density. They found that non-observance doses of vitamin D 400 IU/day with calcium supplementation maintained bone mineral density in a group of corticosteroid using rheumatology patients, higher doses of more potent 1,25-dihydroxyvitamin D were of no benefit and led to raised serum and urine calcium concentrations.2

Although low dose vitamin D therapy (400–600 IU/day) in postgastrectomy patients is likely nontoxic—that is, in terms of effects on calcium, this remains to be proved in a systematic fashion. The benefit of this therapy in postgastrectomy patients certainly needs to be proved and has not been in Bisballe et al’s paper.

G N BERNSTEIN
Division of Gastroenterology,
UCLA Department of Medicine,
Los Angeles, California, USA

Reply

Sir,—We thank Dr Bernstein for his constructive comments on our paper on osteomalacia in postgastrectomy patients and his emphasis on the importance of the problem. We also consider bone disease after gastrectomy a problem very often ignored in daily clinical practice.

The diagnosis of osteomalacia in our study was based on very stringent histological criteria, which delineate severe mineralisation defects affecting virtually all bone surfaces. The remaining patients with abnormal bone histology revealed varying degrees of secondary hyperparathyroidism with focal areas of mineralisation defects—that is, earlier stages in the osteomalacic process. Further analysis of serum biochemistry in these patients was hampered by the lack of good parathyroid hormone assays (the study was performed before the advent of assays for intact parathyroid hormone [1–84]). Theoretically, such patients would also benefit from vitamin D supplementation, because the high turnover state associated with secondary hyperparathyroidism leads to osteopenia. We do not think, however, that the study on Crohn’s disease by Vogelsang et al1 is of great relevance in this respect. The bone in patients with Crohn’s disease is characterised by osteopenia and not by discrete osteomalacia demonstrable.2

We do not advocate the use of more potent analogues (1-alpha-vitamin D3 or 1,25(OH)2D3) for gastrectomy patients. We agree with Dr Bernstein that these compounds demand close monitoring because of the risk for severe intoxication. We have, however, administered daily doses of 18 000 IU calcium carbonate (D3) over a five year period to more than 200 osteoporotic women (mean age 65 years) without any cases of vitamin D intoxication.3 Thus, we do not think that vitamin D supplements are dangerous as long as they are given in the form of D3, analogues in a dose range of 400–800 IU. We agree, however, that a controlled clinical study is necessary in order to test for optimal dose, efficacy and side effects.

E F ERIKSEN
S BISBALLE
I MOSKEILDE
HESSE0
O H SØRENSEN

Department of Endocrinology,
Gastrointestinal Surgery and Pathology,
Aarhus University Hospital, Aarhus, Denmark
and Department of Internal Medicine,
Sundby Hospital, Copenhagen, Denmark

Osteomalacia after gastrectomy.

C N Bernstein

_Gut_ 1992 33: 1151-1152
doi: 10.1136/gut.33.8.1151-a

Updated information and services can be found at:
_http://gut.bmj.com/content/33/8/1151.2.citation_

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
_http://group.bmj.com/group/rights-licensing/permissions_

To order reprints go to:
_http://journals.bmj.com/cgi/reprintform_

To subscribe to BMJ go to:
_http://group.bmj.com/subscribe/_{/}